[{"id":"elipse-ldlc","name":"Percent change in LDL-C at Week 24","type":"PRIMARY","unit":"%","results":[{"notes":"-47% LDL-C reduction from baseline","value":-47,"arm_id":"evinacumab-elipse","arm_name":"Evinacumab"},{"notes":"+2% LDL-C change","value":2,"arm_id":"placebo-elipse","arm_name":"Placebo"},{"notes":"Treatment difference -49% (95% CI -65 to -33), p<0.0001","value":-49,"arm_id":"treatment-diff","p_value":"<0.0001","arm_name":"Difference","ci_lower":-65,"ci_upper":-33}],"timepoint":"Week 24","description":"Percent change from baseline in LDL-cholesterol. HoFH patients have severely elevated LDL-C (mean baseline ~255 mg/dL) due to absent/defective LDL receptors. Evinacumab works independently of LDLR via ANGPTL3 inhibition."}]

ELIPSE met primary endpoint: -47% LDL-C reduction with evinacumab vs +2% placebo (difference -49%, p<0.0001). Also reduced ApoB -37%, TG -50%, non-HDL-C -52%. First therapy to work independently of LDL receptors — critical for HoFH patients with no functional LDLR.

ELIPSE (n=65, 24 weeks): Nasopharyngitis 16%, influenza-like 7%, infusion reactions 7%, anaphylaxis 1% (1 patient). Discontinuation 2%. Overall well-tolerated for an ultra-rare disease population.

ELIPSE is remarkable: -47% LDL-C reduction in patients where essentially nothing else works. HoFH patients with null LDLR mutations got -49% reduction. This is first-in-class, mechanism-differentiated, and addresses a severe unmet need. Small market (~1,300 US patients) but high per-patient value.

HoFH patients have absent/defective LDL receptors, making PCSK9 inhibitors and statins (which upregulate LDLR) less effective. ANGPTL3 inhibition reduces LDL-C via an LDLR-independent mechanism (enhanced lipoprotein lipase and endothelial lipase activity).